Dynavax (DVAX) stock gains as the company's Z-1018 shingles shot shows immune response comparable to GSK's (GSK) Shingrix vaccine in a Phase 1/2 trial. Read more here.

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in ...

Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Dynavax ( (DVAX)) is now available. On August 21, 2025, Dynavax ...

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Dynavax Technologies Corporation (NASDAQ:DVAX) surged 8% Thursday following the announcement of encouraging topline data from ...

Detailed price information for Dynavax Technologies (DVAX-Q) from The Globe and Mail including charting and trades.

Vaccination rates are declining in US school children, and primary care doctors often face resistance. Four primary care ...

Investing.com -- Dynavax Technologies Corporation (NASDAQ: DVAX) stock soared 8% Thursday after the company announced positive topline results from its Phase 1/2 clinical trial for Z-1018, its ...